Administration of exogenous tissue plasminogen activator reduces oedema in mice lacking the tissue plasminogen activator gene

Clinical and Experimental Pharmacology and Physiology

Volumn 31, Issue 5-6, 2004, Pages 327-330

  Stringer, Kathleen A ^a   Dunn, John S ^a   Gustafson, Daniel L ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Acute inflammation; Carrageenan; Myeloperoxidase; Neutrophils; Oedema; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; CARRAGEENAN; MYELOPEROXIDASE; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; EDEMA; ENZYME ACTIVITY; FOOT PAD; GENE; HYPOTHESIS; INJECTION; INJURY; KNOCKOUT MOUSE; MEASUREMENT; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; RESPIRATORY DISTRESS SYNDROME; RHEUMATOID ARTHRITIS; TISSUE PLASMINOGEN ACTIVATOR GENE; WILD TYPE;

ANIMALS; EDEMA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; TISSUE PLASMINOGEN ACTIVATOR;

EID: 3042585854     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2004.03999.x     Document Type: Article

References (29)

1. Idell S, Koenig KB, Fair DS, Martin TR, McLarty J, Maunder RJ. Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am. J. Physiol. 1991; 261: L240-8.
2. Idell S, James KK, Levin EF et al. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J. Clin. Invest. 1989; 84: 695-705.
3. Marshall BC, Sageser DS, Rao NV, Emi M, Hoidal JR. Alveolar epithelial cell plasminogen activator. J. Biol. Chem. 1990; 265: 8198-204.
4. Bertozzi P, Astedt B, Zenzius L et al. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N. Engl. J. Med. 1990; 322: 890-7.
5. Cooper P, Potter S, Mueck B, Yousefi S, Jarai G. Identification of genes induced by inflammatory cytokines in airway epithelium. Am. J. Physiol. 2001; 280: L841-52.
6. Yang YH, Carmeliet P, Hamilton JA. Tissue-type plasminogen activator deficiency exacerbates arthritis. J. Immunol. 2001; 167: 1047-52.
7. Busso N, So A. Urokinase in rheumatoid arthritis: Causal or coincidental? Ann. Rheum. Dis. 1997; 56: 705-6.
8. Cook AD, Braine EL, Campbell IK, Hamilton JA. Differing roles for urokinase and tissue-type plasminogen activator in collagen-induced arthritis. Am. J. Pathol. 2002; 160: 917-26.
9. Belcher C, Fawthrop F, Bunning R, Doherty M. Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees. Ann. Rheum. Dis. 1996; 55: 230-6.
10. Ronday HK, Smits HH, Van Muijen GNP et al. Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Br. J. Rheumatol. 1996; 35: 416-23.
11. Busso N, Peclat V, So A, Sappino A-P. Plasminogen activation in synovial tissues: Differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann. Rheum. Dis. 1997; 56: 550-7.
12. Stringer KA, Lindenfeld J, Repine AJ, Cohen Z, Repine JE. Tissue plasminogen activator (tPA) inhibits human neutrophil superoxide anion production in vitro. Inflammation 1997; 21: 27-34.
13. Riesenberg K, Schlaeffer F, Katz A, Levy R. Inhibition of superoxide production in human neutrophils by combinations of heparin and thrombolytic agents. Br. Heart J. 1995; 73: 14-19.
14. Mehta JL, Mehta P, Lawson DL, Herzbrun L. Tissue plasminogen activator and plasmin independently decrease human neutrophil activation. Life Sci. 1989; 45: 1665-9.
15. Stringer KA, Bose SK, McCord JM. Antiinflammatory activity of tissue plasminogen activator in the carrageenan rat footpad model. Free Radic. Biol. Med. 1997; 22: 985-8.
16. Stringer KA, Hybertson BM, Cho OJ, Cohen Z, Repine JE. Tissue plasminogen activator (tPA) inhibits interleukin-1 induced acute lung leak. Free Radic. Biol. Med. 1998; 25: 184-8.
17. Brommer EJP, Dooijewaard G, Dijkmans BAC, Breeveld FC. Plasminogen activators in synovial fluid and plasma from patients with arthritis. Ann. Rheum. Dis. 1992; 51: 965-8.
18. Winter CA, Flataker L. Reaction thresholds to pressure in edematous hindpaws and responses to analgesic drugs. J. Pharmacol. Exp. Ther. 1965; 150: 165-70.
19. Vinegar R, Truax JF, Selph JL, Johnston PR, Venable AL, McKenzie KK. Pathway to carrageenan-induced inflammation in the hind limb of the rat. Fed. Proc. 1987; 46: 118-26.
20. Ando Y, Inoue M, Araki S, Morino Y. Inhibition of carrageenan-induced paw edema by a superoxide dismutase derivative that circulates bound to albumin. Biochim. Biophys. Acta 1991; 1073: 374-9.
21. Vinegar R, Truax J, Selph JL. Quantitative studies of the pathway to acute carrageenin inflammation. Fed. Proc. 1976; 35: 2447-56.
22. Vinegar R, Schreiber W, Hugo R. Biphasic development of carrageenin edema in rats. J. Pharmacol. Exp. Ther. 1969; 166: 96-103.
23. Vinegar R, Truax J, Selph JL, Lea AL, Johnston PR. Quantitative in vivo studies of the acute actions of the anti-inflammatory drugs in the rat. Eur J. Rheumatol Inflamm. 1978; 1: 204-11.
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J. Biol. Chem. 1951; 193: 265-75.
25. Xia Y, Zweier JL. Measurement of myeloperoxidase in leukocyte-containing tissues. Anal. Biochem. 1997; 245: 93-6.
26. Busso N, Peclat V, Van Ness K et al. Exacerbation of antigen-induced arthritis in urokinase-deficient mice. J. Clin. Invest. 1998; 102: 41-50.
27. Idell S. Endothelium and disordered fibrin turnover in the injured lung: Newly recognized pathways. Crit. Care Med. 2002; 30 (Suppl.): S274-80.
28. Korninger C, Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and various animal species in vitro. Thromb. Haemost. 1981; 46: 561-5.
29. 2, and PAF. J. Clin. Invest. 1998; 101: 890-8.